Minimizing the Risk of Posttransplant Malignancy

Transplantation Proceedings

Volumn 40, Issue 10 SUPPL., 2008, Pages

  Campistol, J M ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CALCINEURIN INHIBITOR; CYCLOSPORIN A; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS; TEMSIROLIMUS;

ACUTE GRAFT REJECTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BURKITT LYMPHOMA; CANCER RISK; CARDIOVASCULAR DISEASE; DRUG SUBSTITUTION; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CARCINOMA; LOW CALORY DIET; METASTASIS; MORTALITY; NEOPLASM; ONCOVIRINA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN RESTRICTION; RISK; SURVIVAL; TOBACCO; TUMOR GROWTH;

CALCINEURIN; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; NEOPLASMS; RETROVIRIDAE; SIROLIMUS; SKIN NEOPLASMS; TRANSPLANTATION IMMUNOLOGY;

EID: 57649109628     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.10.015     Document Type: Article

References (25)

1. OPTN/SRTR 2006 Annual Report. Available at http://www.ustransplant.org/annual_Reports
2. Meier-Kreische H.U., Schold J.D., Srinivas T.R., et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 4 (2004) 378
3. Nankivell B.J., Borrows R.J., Fung C.L.-S., et al. The natural history of chronic allograft nephropathy. N Engl J Med 349 (2003) 2326
4. Ojo A.O., Hanson J.A., Wolfe R.A., et al. Long-term survival in renal transplant recipients with graft function. Kidney Int 57 (2000) 307
5. ANZDATA Registry 2006 Report. Available at: http://www.anzdata.org.au/anzdata/AnzdataReport
6. Webster A.C., Craig J.C., Simpson J.M., et al. Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15,183 recipients. Am J Transplant 7 (2007) 2140
7. Johnson S.R., Cherikh W.S., Kauffman H.M., et al. Retransplantation after post-transplant lymphoproliferative disorders: an OPTN/UNOS database analysis. Am J Transplant 6 (2006) 2743
8. Cherikh W.S., Christenson L.J., Kauffman H.M., et al. The Effect of Post-Transplant Non-Melanoma Skin Cancer on Survival. Am J Transplant 7 Suppl 2 (2007) 318
9. Kasiske B.L., Snyder J.J., Gilbertson D.T., et al. Cancer after kidney transplantation in the United States. Am J Transplant 4 (2004) 905
10. Tremblay F., Fernandes M., Habbab F., et al. Malignancy after renal transplantation: incidence and role of type of immunosuppression. Ann Surg Oncol 9 (2002) 785
11. de Jong-Tieben L.M., Berkhout R.J., ter Schegget J., et al. The prevalence of human papillomavirus DNA in benign keratotic skin lesions of renal transplant 1 recipients with and without a history of skin cancer is equally high: a clinical study to assess risk factors for keratotic skin lesions and skin cancer. Transplantation 69 (2000) 44
12. Harwood C.A., Surentheran T., McGregor J.M., et al. Human papillomavirus infection and non-melanoma skin cancer in immunosuppressed and immunocompetent individuals. J Med Virol 61 (2000) 289
13. Nobbenhuis M.A., Walboomers J.M., Helmerhorst T.J., et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 354 (1999) 20
14. Paya C.V., Fung J.J., Nalesnik M.A., et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. Transplantation 68 (1999) 1517
15. Moosa M.R., Treurnicht F.K., van Rensburg E.J., et al. Detection and subtyping of human herpesvirus-8 in renal transplant patients before and after remission of Kaposi's sarcoma. Transplantation 66 (1998) 214
16. Ridruejo E., Mandó O.G., Dávalos M., et al. Hepatocellular carcinoma in renal transplant patients. Transplant Proc 37 (2005) 2086
17. Dantal J., Hourmant M., Cantarovich D., et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 351 (1998) 623
18. Wimmer C.D., Rentsch M., Crispin A., et al. The janus face of immunosuppression - de novo malignancy after renal transplantation: the experience of the Transplantation Center Munich. Kidney Int 71 (2007) 1271
19. Hojo M., Morimoto T., Maluccio M., et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 397 (1999) 530
20. Campistol J.M., Albanell J., Arns W., et al. Use of proliferation signal inhibitors in the management of post-transplant malignancies-clinical guidance. Nephrol Dial Transplant 22 Suppl 1 (2007) i36
21. Campistol J.M., Gutierrez-Dalmau A., and Torregrosa J.V. Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma. Transplantation 77 (2004) 760
22. Stallone G., Schena A., Infante B., et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 352 (2005) 1317
23. Kauffman H.M., Cherikh W.S., Cheng Y., et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 80 (2005) 883
24. Campistol J.M., Eris J., Oberbauer R., et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 17 (2006) 581
25. Alberu J., Schena F.P., Wali R., et al. Lower malignancy rates in renal allograft recipients converted to sirolimus (SRL)-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial. J Am Soc Nephrol 17 (2006) 18A